|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer Statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar
|
|
3
|
Schnitt SJ: Classification and prognosis
of invasive breast cancer: from morphology to molecular taxonomy.
Mod Pathol. 23:S60–S64. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rakha EA and Ellis IO: Modern
classification of breast cancer: should we stick with morphology or
convert to molecular profile characteristics. Adv Anat Pathol.
18:255–267. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rakha EA, Reis-Filho JS, Baehner F, et al:
Breast cancer prognostic classification in the molecular era: the
role of histological grade. Breast Cancer Res.
12:2072010.PubMed/NCBI
|
|
6
|
Perou CM, Sørlie T, Eisen MB, et al:
Molecular portraits of human breast tumours. Nature. 406:747–752.
2000. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Murphy N, Millar E and Lee CS: Gene
expression profiling in breast cancer: towards individualising
patient management. Pathology. 37:271–277. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Correa Geyer F and Reis-Filho JS:
Microarray-based gene expression profiling as a clinical tool for
breast cancer management: are we there yet? Int J Surg Pathol.
17:285–302. 2009.PubMed/NCBI
|
|
9
|
Tyers M and Mann M: From genomics to
proteomics. Nature. 422:193–197. 2003. View Article : Google Scholar
|
|
10
|
Bertucci F, Birnbaum D and Goncalves A:
Proteomics of breast cancer: principles and potential clinical
applications. Mol Cell Proteomics. 5:1772–1786. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Westley B and Rochefort H: A secreted
glycoprotein induced by estrogen in human breast cancer cell lines.
Cell. 20:353–362. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Trask DK, Band V, Zajchowski DA, Yaswen P,
Suh T and Sager R: Keratins as markers that distinguish normal and
tumor-derived mammary epithelial cells. Proc Natl Acad Sci USA.
87:2319–2323. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Stein RC and Zvelebil MJ: The application
of 2-D gel-based proteomics methods to the study of breast cancer.
J Mammary Gland Biol Neoplasia. 7:385–393. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Umar A, Kang H, Timmermans AM, et al:
Identification of a putative protein profile associated with
tamoxifen therapy resistance in breast cancer. Mol Cell Proteomics.
8:1278–1294. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Besada V, Diaz M, Becker M, Ramos Y,
Castellanos-Serra L and Fichtner I: Proteomics of xenografted human
breast cancer indicates novel targets related to tamoxifen
resistance. Proteomics. 6:1038–1048. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
González-Zamorano M, Mendoza-Hernández G,
Xolalpa W, Parada C, Vallecillo AJ, Bigi F and Espitia C:
Mycobacterium tuberculosis glycoproteomics based on
ConA-lectin affinity capture of mannosylated proteins. J Proteome
Res. 8:721–733. 2009.
|
|
17
|
Zhang D, Tai LK, Wong LL, Chiu LL, Sethi
SK and Koay ES: Proteomic study reveals that proteins involved in
metabolic and detoxification pathways are highly expressed in
HER-2/neu-positive breast cancer. Mol Cell Proteomics. 4:1686–1696.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chang XZ, Li DQ, Hou YF, Wu J, Lu JS, Di
GH, Jin W, Ou ZL, Shen ZZ and Shao ZM: Identification of the
functional role of peroxiredoxin 6 in the progression of breast
cancer. Breast Cancer Res. 9:R762007. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Le Naour F, Misek DE, Krause MC, Deneux L,
Giordano TJ, Scholl S and Hanash SM: Proteomics-based
identification of RS/DJ-1 as a novel circulating tumor antigen in
breast cancer. Clin Cancer Res. 7:3328–3335. 2001.PubMed/NCBI
|
|
20
|
Bianchi MS, Bianchi NO and Bolzán AD:
Superoxide dismutase activity and superoxide dismutase-1 gene
methylation in normal and tumoral human breast tissues. Cancer
Genet Cytogenet. 59:26–29. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wei L, Liu TT, Wang HH, Hong HM, Yu AL,
Feng HP and Chang WW: Hsp27 participates in the maintenance of
breast cancer stem cells through regulation of
epithelial-mesenchymal transition and nuclear factor-kappa B.
Breast Cancer Res. 13:R1012011. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sims JD, McCready J and Jay DG:
Extracellular heat shock protein (Hsp)70 and Hsp90α assist in
matrix metalloproteinase-2 activation and breast cancer cell
migration and invasion. PLoS One. 6:e188482011.
|
|
23
|
Wang LP, Bi J, Yao C, Xu XD, Li XX, Wang
SM, Li ZL, Zhang DY, Wang M and Chang GQ: Annexin A1 expression and
its prognostic significance in human breast cancer. Neoplasma.
57:253–259. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Porter D, Weremowicz S, Chin K, et al: A
neural survival factor is a candidate oncogene in breast cancer.
Proc Natl Acad Sci USA. 100:10931–10936. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sahni A, Arévalo MT, Sahni SK and
Simpson-Haidaris PJ: The VE-cadherin binding domain of fibrinogen
induces endothelial barrier permeability and enhances
transendothelial migration of malignant breast epithelial cells.
Int J Cancer. 125:577–584. 2009. View Article : Google Scholar
|
|
26
|
Moon HG, Jeong SH, Ju YT, Jeong CY, Lee
JS, Lee YJ, Hong SC, Choi SK, Ha WS, Park ST and Jung EJ:
Up-regulation of RhoGDI2 in human breast cancer and its prognostic
implications. Cancer Res Treat. 42:151–156. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Steeg PS, De la Rosa A, Flatow U,
MacDonald NJ, Benedict M and Leone A: Nm23 and breast cancer
metastasis. Breast Cancer Res Treat. 25:175–187. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Thornalley PJ: Protecting the genome:
defence against nucleotide glycation and emerging role of
glyoxalase I overexpression in multidrug resistance in cancer
chemotherapy. Biochem Soc Trans. 31:1372–1377. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Knauer M, Cardoso F, Wesseling J, Bedard
PL, Linn SC, Rutgers EJ and van’t Veer LJ: Identification of a
low-risk subgroup of HER-2-positive breast cancer by the 70-gene
prognosis signature. Br J Cancer. 103:1788–1793. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Toi M, Iwata H, Yamanaka T, et al Japan
Breast Cancer Research Group-Translational Research Group: Clinical
significance of the 21-gene signature (Oncotype DX) in hormone
receptor-positive early stage primary breast cancer in the Japanese
population. Cancer. 116:3112–3118. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pitkanen-Arsiola T, Tillman J, Gu G, et
al: Androgen and anti-androgen treatment modulates androgen
receptor activity and DJ-1 stability. Prostate. 66:1177–1193. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tillman J, Yuan J, Gu G, et al: DJ-1 binds
androgen receptor directly and mediates its activity in hormonally
treated prostate cancer cells. Cancer Res. 67:4630–4637. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ranganathan S and Tew KD: Analysis of
glyoxalase-I from normal and tumor tissue from human colon. Biochim
Biophys Acta. 1182:311–316. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Di Ilio C, Angelucci S, Pennelli A, Zezza
A, Tenaglia R and Sacchetta P: Glyoxalase activities in tumor and
non-tumor human urogenital tissues. Cancer Lett. 96:189–193.
1995.PubMed/NCBI
|
|
35
|
Davidson SD, Cherry JP, Choudhury MS,
Tazaki H, Mallouh C and Konno S: Glyoxalase I activity in human
prostate cancer: a potential marker and importance in chemotherapy.
J Urol. 161:690–691. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rulli A, Carli L, Romani R, Baroni T,
Giovannini E, Rosi G and Talesa V: Expression of glyoxalase I and
II in normal and breast cancer tissues. Breast Cancer Res Treat.
66:67–72. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bair WB III, Cabello CM, Uchida K, Bause
AS and Wondra GT: GLO1 overexpression in human malignant melanoma.
Melanoma Res. 20:85–96. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sakamoto H, Mashima T, Kizaki A, Dan S,
Hashimoto Y, Naito M and Tsuruo T: Glyoxalase I is involved in
resistance of human leukemia cells to antitumor agent-induced
apoptosis. Blood. 95:3214–3218. 2000.PubMed/NCBI
|
|
39
|
Santarius T, Bignell GR, Greenman CD, et
al: GLO1 - a novel amplified gene in human cancer. Genes
Chromosomes Cancer. 49:711–725. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Van der Heiden MG, Cantley LC and Thompson
CB: Understanding the Warburg effect: the metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009.PubMed/NCBI
|
|
41
|
Ross JS and Harbeck N: Prognostic and
predictive factors overview. Molecular Oncology of Breast Cancer.
Ross JS and Hortobagyi GN: Jones and Bartlett Publishers; Sudbury,
MA: 2005
|
